• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Forum Markets Incorporated filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    4/3/26 4:19:12 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FRMM alert in real time by email
    false 0001690080 0001690080 2026-04-02 2026-04-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): April 2, 2026

     

    Forum Markets, Incorporated

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38105   90-1890354
    (State or Other Jurisdiction
    of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    2875 South Ocean Blvd, Suite 200
    Palm Beach, FL
      33480
    (Address of Principal Executive Offices)   (Zip Code)

     

    (650) 507-0669

    (Registrant’s telephone number, including area code)

     

     

    (Former name or former address, if changed since last report)

      

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

      

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   FRMM   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On April 2, 2026, the Board of Directors of Forum Markets, Incorporated (the “Company”), upon the recommendation of the Compensation Committee of the Board, approved (a) a one-time initial equity award and a pro-rated 2025 annual award to McAndrew Rudisill, the Chief Executive Officer and Chairman of the Company, and (b) an equity award to John Saunders, the Chief Financial Officer of the Company. Each award consists 60% of performance stock units (“PSUs”) and 40% of restricted stock units (“RSUs”) and was granted on April 2, 2026 pursuant to the Company’s 2025 Omnibus Incentive Plan (the “2025 OIP”) and a Performance Stock Unit Award Agreement (for the PSUs) and a Restricted Stock Unit Award Agreement (for the RSUs). It is anticipated that Mr. Rudisill will be granted a similar annual equity award on the date of each annual meeting of the Company’s stockholders beginning with the 2026 annual meeting, subject to review and approval by the Compensation Committee.

     

    In its recommendation to the Board, the Compensation Committee explained its view that it was an important governance and retention matter to grant appropriate equity awards to Mr. Rudisill and Mr. Saunders, to retain and motivate them and to align their interests with the Company’s shareholders. In reaching its recommendation about the amount and structure of the awards, the Compensation Committee engaged an independent compensation consultant, reviewed market data provided by the consultant, conferred with outside counsel, and met multiple times as a Committee to discuss the amounts and structure of the awards. The Committee also considered the facts that Mr. Rudisill had received no equity compensation since joining the Company and that he currently holds no unvested equity in the Company (on November 12, 2025, 136,500 shares of restricted common stock were granted to Mr. Rudisill; on December 1, 2025, that grant was rescinded by the Board, with the approval of Mr. Rudisill, effective as of the grant date). In its recommendation to the Board, the Compensation Committee explained that, as a result of these considerations, the members of the Committee unanimously concluded that granting the awards would be in the Company’s best interest.

     

    The one-time initial equity award was granted in recognition of Mr. Rudisill’s appointment to lead the Company’s strategic direction and has a grant date value of $4,285,500, which is two times the $2,142,750 grant date value of the annual equity award that is anticipated will be granted to Mr. Rudisill on the date of each annual meeting of stockholders. The pro-rated 2025 annual award was granted in recognition of Mr. Rudisill’s service from August 1, 2025 to December 31, 2025 and has a grant date value of $898,194, which reflects the prorated value of the anticipated annual equity award. The equity award granted to Mr. Saunders has a grant date value of $750,000. The number of shares of the Company’s common stock subject to each of the awards was determined by dividing the applicable grant date value by the closing price of a share on the grant date. To the extent that the awards vest, the shares will be delivered to Mr. Rudisill or Mr. Saunders on or promptly following the vesting date.

     

    For each award, the RSUs will vest in one-third installments on each of the first, second and third anniversaries of August 1, 2025 (the start date for both Mr. Rudisill and Mr. Saunders), subject to continued employment through the applicable anniversary, and the PSUs will vest based on the achievement of Company share price hurdles within five years after the grant date, subject to continued employment through the date that the applicable hurdle is achieved (or, if later, the date that the applicable minimum vesting period described below is met). One-third of the PSUs will vest at a share price hurdle of $5.00, an additional one-third of the PSUs will vest at a share price hurdle of $7.50, and the final one-third of the PSUs will vest at a share price hurdle of $10.00. Each share price hurdle will be achieved if the closing price of a share equals or exceeds the applicable hurdle for at least 30 trading days within any consecutive 60 calendar day period. Any PSUs for which the applicable share price hurdle is not met within five years after the grant date will be forfeited. Each tranche of the PSUs is also subject to a minimum vesting period that applies regardless of when the applicable share price hurdle is met, such that, except as described below, the $5.00 tranche may not vest earlier than the first anniversary of the grant date, the $7.50 tranche may not vest earlier than the second anniversary of the grant date, and the $10.00 tranche may not vest earlier than the third anniversary of the grant date.

     

    On termination of Mr. Rudisill’s or Mr. Saunders’ employment by the Company without “Cause” (as defined in the 2025 OIP) at any time prior to a “Change in Control” (as defined in the 2025 OIP), any unvested RSUs and any PSUs for which the applicable share price hurdles were previously achieved but which have not yet vested will vest, and any PSUs for which the applicable share price hurdles were not previously achieved will be forfeited. On a Change in Control, the share price hurdles for the PSUs will be deemed achieved (to the extent not previously achieved), and following the Change in Control, the RSUs and the PSUs (to the extent not previously vested) will continue to vest on their existing schedules, with vesting accelerating if Mr. Rudisill’s or Mr. Saunder’s employment is subsequently terminated by the Company without Cause or by him for “Good Reason” (as defined in the 2025 OIP).

     

    1

     

     

    The foregoing description of the equity awards granted to Mr. Rudisill and Mr. Saunders is a general description only and is qualified in its entirety by the full text of the Performance Stock Unit Award Agreement and the Restricted Stock Unit Award Agreement, copies of which are attached as Exhibit 10.1 and Exhibit 10.2, respectively.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Exhibit
    10.1   Performance Stock Unit Award Agreement
    10.2   Restricted Stock Unit Award Agreement
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

      

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      FORUM MARKETS, INCORPORATED
     
    Date: April 3, 2026 By: /s/ McAndrew Rudisill
        Name:  McAndrew Rudisill
        Title: Chief Executive Officer

     

    3

     

    Get the next $FRMM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FRMM

    DatePrice TargetRatingAnalyst
    4/7/2026$5.00Speculative Buy
    The Benchmark Company
    More analyst ratings

    $FRMM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on Forum Markets with a new price target

    The Benchmark Company initiated coverage of Forum Markets with a rating of Speculative Buy and set a new price target of $5.00

    4/7/26 8:46:27 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Dalton Angela

    4 - FORUM MARKETS Inc (0001690080) (Issuer)

    4/6/26 8:15:10 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Dalton Angela

    3 - FORUM MARKETS Inc (0001690080) (Issuer)

    4/6/26 7:46:15 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Edwards Michael A

    4 - FORUM MARKETS Inc (0001690080) (Issuer)

    4/3/26 7:10:48 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    SEC Filings

    View All

    SEC Form EFFECT filed by Forum Markets Incorporated

    EFFECT - FORUM MARKETS Inc (0001690080) (Filer)

    4/10/26 12:15:03 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forum Markets Incorporated filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - FORUM MARKETS Inc (0001690080) (Filer)

    4/8/26 9:06:39 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Forum Markets Incorporated

    424B3 - FORUM MARKETS Inc (0001690080) (Filer)

    4/8/26 8:29:06 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Forum Announces Initiation of Analyst Coverage by Benchmark

    Benchmark Initiates with Speculative Buy Rating and $5.00 Price TargetPALM BEACH, Fla., April 7, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM), a digital asset platform modernizing capital markets through the tokenization of real-world assets on Ethereum, today announced that The Benchmark Company, LLC, a StoneX company, has initiated coverage of Forum's common stock with a Speculative Buy rating and a price target of $5.00 per share. The initiation, published by Benchmark analyst, Mark Palmer, on April 7, 2026, highlights Forum's position as a pure-play early m

    4/7/26 2:43:00 PM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forum Reports Fourth Quarter and Full Year 2025 Financial Results

    Company Introduces 2026 Guidance as RWA Tokenization Platform Begins to Scale PALM BEACH, Fla., March 31, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM) ("Forum" or the "Company"), a digital asset platform modernizing capital markets through the tokenization of real-world assets on Ethereum, today reported financial results for the fourth quarter and full year ended December 31, 2025. "In less than a year, Forum has moved from concept to execution: from building the infrastructure, establishing key partnerships, and validating our technology, to generating revenu

    3/31/26 9:00:00 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Forum to Present at Sidoti's Small-Cap Virtual Investor Conference on March 18

    PALM BEACH, Fla., March 12, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM) ("Forum"), a digital asset platform modernizing capital markets through the tokenization of real-world assets on Ethereum, today announced that McAndrew Rudisill, chairman and CEO, and John Kristoff, senior vice president, corporate communications and investor relations, are expected to participate in the Sidoti Small-Cap Virtual Investor Conference on Wednesday, March 18, 2026.  The company will participate in a group presentation at 2:30 PM EDT and will also host virtual one-on-one meeti

    3/12/26 9:00:00 AM ET
    $ETHZ
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    Leadership Updates

    Live Leadership Updates

    View All

    Forum Appoints Robert Spake as General Counsel

    PALM BEACH, Fla., March 3, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM), a digital asset platform modernizing capital markets through the tokenization of real-world assets on Ethereum, today announced the appointment of Robert Spake as the company's general counsel. Spake's deep legal expertise in capital markets, tokenization, and regulatory compliance strengthens Forum's leadership team and sharpens its focus on launching compliant, institutionally structured real-world asset products within evolving regulatory frameworks.  "Robert joins Forum at a pivotal mo

    3/3/26 9:00:00 AM ET
    $ETHZ
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FRMM
    Financials

    Live finance-specific insights

    View All

    Forum Reports Fourth Quarter and Full Year 2025 Financial Results

    Company Introduces 2026 Guidance as RWA Tokenization Platform Begins to Scale PALM BEACH, Fla., March 31, 2026 /PRNewswire/ -- Forum Markets, Incorporated (NASDAQ:FRMM) ("Forum" or the "Company"), a digital asset platform modernizing capital markets through the tokenization of real-world assets on Ethereum, today reported financial results for the fourth quarter and full year ended December 31, 2025. "In less than a year, Forum has moved from concept to execution: from building the infrastructure, establishing key partnerships, and validating our technology, to generating revenu

    3/31/26 9:00:00 AM ET
    $FRMM
    Biotechnology: Pharmaceutical Preparations
    Health Care